trial · primary record
Combining nimotuzumab and toripalimab with nab-paclitaxel plus cisplatin
Head and Neck Squamous Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 86 |
| Primary completion | 2030-10 |
| Primary endpoint | MPR Major Pathological Response |
| Registry ID | NCT07906587 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:45.888Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07906587
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.